Meloxicam was administered orally at 10 mg/day

2 trials

Sponsors

Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine

Conditions

sporadic desmoid tumor

Unknown Phase

The nuclear expression of beta-catenin as a prognostic marker of sporadic desmoid tumors with meloxicam

Active, not recruitingJPRN-UMIN000019320

Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicinesporadic desmoid tumor

Start: 2003-02-01Target: 31Updated: 2026-06-29

The CTNNB1 mutaion as a prognostic marker of sporadic desmoid tumors with meloxicam

Active, not recruitingJPRN-UMIN000019321

Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicinesporadic desmoid tumor

Start: 2003-01-01Target: 33Updated: 2026-06-29